Al Sandrock (Biogen via YouTube)

Wav­ing off re­cent PhII flop, Bio­gen trum­pets ear­ly pos­i­tive Alzheimer's da­ta for an­ti-tau an­ti­sense

Even as Bio­gen ex­ecs scram­bled to de­fend Aduhelm and paint a rosy fu­ture the drug promis­es to un­leash, R&D chief Al San­drock re­as­sured an­a­lysts dur­ing a re­cent earn­ings call that his team had more Alzheimer’s tricks.

In par­tic­u­lar, he em­pha­sized his be­lief in tau as a po­ten­tial tar­get — even though go­suranemab, the lead an­ti-tau an­ti­body, had just failed a Phase II study.

“Where­as we have dis­con­tin­ued the BI­IB092 pro­gram, we are con­tin­u­ing the de­vel­op­ment of BI­IB080, our an­ti­sense oligonu­cleotide, which aims to re­duce the pro­duc­tion of all forms of tau both in­tra and ex­tra­cel­lu­lar,” he said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.